MedTrace Logo

Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia

NCT01149018 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2010-06-23

No results posted yet for this study

Summary

The objective of the study is to evaluate the effectiveness of oral tetrahydrocannabinol in patients suffering from Fibromyalgia

Conditions

  • Fibromyalgia

Interventions

DRUG

Tetrahydrocannabinol

Oral solution of THC in concentration of 5mg/0.2ml. Dose regimen: 5mg 2-4 times/day as tolerated.

DRUG

Placebo

Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated

Sponsors & Collaborators

  • Hebrew University of Jerusalem

    collaborator OTHER

  • Hadassah Medical Organization

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-07-31
Completion
2012-10-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01149018 on ClinicalTrials.gov